Expectations for the next FOMC meeting have seen odds of a 50bps rate hike go from extremely unlikely to highly likely
Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

Why Shares of Amphastar Pharmaceuticals Rose Today

01:54pm, Wednesday, 01'st Mar 2023
The company reported a record revenue year and increased EPS.
Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Bill Peters - Chief Financial Officer, Treasurer, Executive Vice Presi
Amphastar stock has generated high rates of post-tax earnings growth with small increments of additional capital investment since FY20. The incremental returns on capital are above historical returns
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Cl

Amphastar: Growth Remains Intact

07:45am, Monday, 14'th Nov 2022
Quarter-over-Quarter growth in revenue has persisted due to the consistent launch of new product pipelines. The overall financial position is substantially strong, which offers significant flexibility
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Ch
Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2
Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.

Amphastar: A Pharmaceutical Growth Stock

09:53am, Thursday, 06'th Oct 2022
Amphastar's profitability and cash flow have been increasing consistently, and with management's efforts, profitability will increase significantly. Having a solid financial position and consistent gr
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE